Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database.
Venner CP, Duggan P, Song K, Reece D, Sharma S, Su J, Jimenez-Zepeda VH, McCurdy A, Louzada M, Mian H, Sebag M, White D, Stakiw J, Kotb R, Aslam M, Reiman A, Gul E, Chu MP, Bergstrom D, LeBlanc R. Venner CP, et al. Among authors: su j. Transplant Cell Ther. 2024 Sep;30(9):889-901. doi: 10.1016/j.jtct.2024.06.030. Epub 2024 Jul 4. Transplant Cell Ther. 2024. PMID: 38971462
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda VH, Su J, Masih-Khan E, Visram A, Louzada M, Song K, White D, Sebag M, Stakiw J, Reiman A, Aslam M, Bergstrom D, Kotb R, Kaedbey R, Gul E, Reece D, Venner CP. McCurdy A, et al. Among authors: su j. Blood Cancer J. 2023 Aug 28;13(1):129. doi: 10.1038/s41408-023-00888-6. Blood Cancer J. 2023. PMID: 37635183 Free PMC article. No abstract available.
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database.
Côté J, LeBlanc R, Mian H, Chu MP, McCurdy A, Masih-Khan E, Su J, Jimenez-Zepeda VH, Song K, Louzada M, White D, Sebag M, Reiman A, Stakiw J, Kotb R, Bergstrom D, Aslam M, Kaedbey R, Venner CP, Gul E, Reece D. Côté J, et al. Among authors: su j. Blood Cancer J. 2023 Sep 5;13(1):137. doi: 10.1038/s41408-023-00905-8. Blood Cancer J. 2023. PMID: 37669949 Free PMC article.
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database.
Kaedbey R, Reece D, Venner CP, McCurdy A, Su J, Chu M, Louzada M, Jimenez-Zepeda VH, Mian H, Song K, Sebag M, Stakiw J, White D, Reiman A, Aslam M, Kotb R, Bergstrom D, Gul E, LeBlanc R. Kaedbey R, et al. Among authors: su j. EJHaem. 2024 Apr 29;5(3):474-484. doi: 10.1002/jha2.894. eCollection 2024 Jun. EJHaem. 2024. PMID: 38895063 Free PMC article.
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial.
McCurdy A, Reece D, Louzada ML, White D, Parkin S, Chu MP, Kotb R, Mian H, Othman I, Su J, Khan A, Gul E, Trudel S. McCurdy A, et al. Among authors: su j. Blood Cancer J. 2024 Sep 11;14(1):155. doi: 10.1038/s41408-024-01135-2. Blood Cancer J. 2024. PMID: 39261451 Free PMC article. Clinical Trial.
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study.
Tanguay M, Roy J, Su J, Gul E, Reece D, Venner CP, White D, Chu MP, Jimenez-Zepada VH, Song K, Mccurdy A, Mian H, Sebag M, Bergstrom D, Stakiw J, Reiman A, Kotb R, Aslam M, Kaedbey R, Louzada M, LeBlanc R. Tanguay M, et al. Among authors: su j. Cancer Med. 2024 Nov;13(21):e70332. doi: 10.1002/cam4.70332. Cancer Med. 2024. PMID: 39499045 Free PMC article.
12,221 results
You have reached the last available page of results. Please see the User Guide for more information.